Profiling the activity of edible European macroalgae towards pharmacological targets for type 2 diabetes mellitus
| Autor: | Alvaro Israel, Brian D. Green, Ciaran Fitzgerald, EP Rafferty, Danielle Calderwood, Francisco Castaneda, Brendan Gilmore, A.R.G. Wylie, Christine A. Maggs, Velizara Stoilova |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
macroalgae
natural products business.industry Incidence (epidemiology) General Engineering enteroendocrine Type 2 Diabetes Mellitus Incretin Anti-diabetic activity Plant Science Aquatic Science Bioinformatics medicine.disease incretin SGLT-2 DPP-4 SDG 3 - Good Health and Well-being Diabetes mellitus drug targets medicine business Dipeptidyl peptidase-4 |
| Zdroj: | Calderwood, D, Rafferty, E, Fitzgerald, C, Stoilova, V, Wylie, A, Gilmore, B F, Castaneda, F, Israel, A, Maggs, C A & Green, B D 2021, ' Profiling the activity of edible European macroalgae towards pharmacological targets for type 2 diabetes mellitus ', Applied Phycology, vol. 2, no. 1, pp. 10-21 . https://doi.org/10.1080/26388081.2020.1852519 |
| ISSN: | 2638-8081 |
| DOI: | 10.1080/26388081.2020.1852519 |
| Popis: | In traditional medicine marine extracts are extensively used as therapies for diabetes. With the increasing rate of incidence of type 2 diabetes mellitus and rising cost of treatments, we investigated the anti-diabetic properties of extracts of common edible seaweeds in Europe including their ability to inhibit alpha-glucosidase and dipeptidyl peptidase 4 (DPP-4) enzymatic activity, block sodium glucose transporter-2 (SGLT-2) activity and stimulate glucagon-like peptide-1 (GLP-1) secretion and synthesis. The most promising seaweed extracts were tested for anti-hyperglycaemic activity in vivo. Some brown seaweed (Phaeophyceae) extracts had inhibitory effects on alpha-glucosidase ranging from 13.9 ± 0.2% to 89.5 ± 0.4% (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|